Stock Financial Ratios


SNSS / Sunesis Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.17
Volume26,300.00
Market Cap ($M)100.87
Enterprise Value ($M)18.76
Book Value ($M)21.02
Book Value / Share1.34
Price / Book34.72
NCAV ($M)32.30
NCAV / Share2.06
Price / NCAV7.20
Income Statement (mra) ($M)
Revenue2.54
EBITDA-36.46
Net Income-38.02
Balance Sheet (mrq) ($M)
Cash & Equivalents7.95
Cash / Share0.51
Assets15.07
Liabilities12.16
Quick Ratio3.95
Current Ratio3.95
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.81
Return on Assets (ROA)-0.88
Return on Equity (ROE)-1.81
Identifiers and Descriptors
CUSIP867328601
Central Index Key (CIK)1061027
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
867328700
867328951
867328900
867328901
867328950
Share Statistics
Common Shares Outstanding (M)34.25
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Other Non Current Per Share0.09
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.00
Assets Current Per Share0.87
Cash Per Share0.51
Minority Interest Per Share0.00
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Accounts Payable Per Share0.00
Debt Per Share0.00
Inventory Per Share0.00
Additional Paid In Capital Per Share39.05
Liabilities And Stock Equity Per Share0.96
Retained Earnings Per Share-39.92
Intangibles Per Share0.00
Equity Per Share0.19
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Cash And Equivalents Per Share0.51
Liabilities Current Per Share0.47
Assets Per Share0.96
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Liabilities Per Share0.78
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00

Related News Stories

Stocks To Watch: Retailers Make Final Holiday Push

2017-12-23 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn on the e-mail alert on to receive this article in your inbox every Saturday morning. (664-4)

ROTY Edition 1 Volume 58: Increasing Contender Coverage And Trades

2017-12-05 seekingalpha
We are swapping another current loser for a Contender that appears to be setting up for a catalyst-filled 2018. (130-5)

Top Analyst Upgrades and Downgrades: Bluebird Bio, Delphi, DowDuPont, Expedia, McDonald’s, Snap, Ulta, Vale and More

2017-12-05 247wallst
Stocks hit records after tax reform passed on Monday, and they were indicated higher yet again on Tuesday. There has been a rotation in recent days out of many of the technology stock leaders that had such big gains in the past year, and that was also the case on Tuesday. The trend that has continued to prevail for more than five years is for investors to buy all the big market sell-offs. Many investors are also hunting for new investing and trading ideas to generate gains and income ahead. (362-1)

BRIEF-Sunesis Pharmaceuticals Inc - Daniel Swisher Resigns As CEO Effective End Of 2017

2017-12-04 reuters
* SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com) (15-0)

ROTY Edition 1 Volume 57: Thoughts On Repatriation, Updates And Swapping For A Contender

2017-12-04 seekingalpha
I reiterate my belief that a change in corporate taxes and repatriation regulation could cause a trend reversal for the IBB and boost biotech sentiment. (302-1)

CUSIP: 867328601